A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma

Abstract Background Primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) are distinct hematological malignancies of B-cell origin that share many biological, molecular, and clinical characteristics. In particular, the JAK/STAT signaling pathway is a driver of tumor develop...

Full description

Bibliographic Details

Published in:	Journal of Experimental & Clinical Cancer Research
Main Authors:	Manon Durand, Vincent Cabaud Gibouin, Laurence Duplomb, Leila Salmi, Mélody Caillot, Brigitte Sola, Vincent Camus, Fabrice Jardin, Carmen Garrido, Gaëtan Jego
Format:	Article
Language:	English
Published:	BMC 2024-05-01
Subjects:	Heat-shock protein XPO1 STAT6 Lymphoma
Online Access:	https://doi.org/10.1186/s13046-024-03068-x